



Our STN: BL125743/0

**MID-CYCLE COMMUNICATION
AGENDA**
August 11, 2021

Green Cross Corporation
Attention: (b) (4)

Dear (b) (4) :

Attached is a copy of the agenda for your August 13, 2021 Mid-Cycle Communication Teleconference with CBER.

Please include a reference to STN BL 125743/0 in your future submissions related to the subject product.

If you have any questions, please contact Nancy Skeeter at nancy.skeeter@fda.hhs.gov

Sincerely,

Basil Golding, MD
Director
Division of Plasma Protein Therapeutics
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research

Mid-Cycle Communication Teleconference Agenda

Application type and number: BL 125743/0

Product name: ALYGLO (immune globulin intravenous, human - stwk), 10% Liquid

Proposed Indication: For the treatment of primary humoral immunodeficiency (PI)

Applicant: Green Cross Corporation

Meeting date & time: Friday, August 13, 2021 3:00-4:30 PM EDT

Committee Chair: Michael Kennedy, PhD

RPM: Nancy Skeeter, MBA

Tentative Attendees:

Nannette Cagungun, MS, PD, RAC, CBER/OTAT/DRPM

Lu Deng, CBER/OCBQ/DBSQC

Nancy Eller, PhD, OTAT/DPPT

Zakaria Ganiyu, MS, MBA, CBER/OTAT/DRPM

Varsha Garnepudi, PhD, CBER/OCBQ/DBSQC

Jie He, CBER/OCBQ/DMPQ

Xiuju (Sue) Lu, PhD, CBER/OCBQ/DMPQ

Michael Kennedy, PhD, CBER/OTAT/DPPT

Vijay Kumar, MD, CBER/OTAT/DCEPT

Leyish Minie, MSN, RN, CBER/OTAT/DRPM

Malgorzata Norton, CBER/OTAT/DPPT

Dorothy Scott, MD, CBER/OTAT/DPPT

Olga Simakova, PhD CBER/OTAT/DPPT/PBD

Ramani Sista, PhD, CBER/OTAT/DRPM

Nancy Skeeter, MBA, CBER/OTAT/DRPM

Million Tegenge, PhD, CBER/OTAT/DCEPT

Lori Tull, CBER/OTAT/DRPM

Maria Luisa Virata, PhD, CBER/OTAT/DPPT

Xiaofei Wang, PhD, CBER/OTAT/DCEPT

Lei Xu, MD, PhD, CBER/OTAT/DCEPT

Agenda:

To provide an update on the status of the review and present substantive issues to the Applicant.

Discussion Summary:

1. Any significant issues/major deficiencies identified by the Review Committee to date.

A. Chemistry, Manufacturing, and Controls (CMC):

1. (NE) Stability data – The updated stability data was received on August 4, 2021 and is currently under review. Storage conditions and shelf-life will be based on review of the available data.
2. (LD) Process Validation:
 - a. All PPQ lots were manufactured at target parameters only. It appears that (b) (4) engineering lots were manufactured to show manufacturing process robustness when running at worst case conditions. The PV report for the engineering lots was received on July 22, 2021 and is currently under review.
 - b. The hold times for (b) (4) were not validated. The (b) (4) have been (b) (4)

B. Clinical:

Verify the underlying condition for labeling purpose; Generalizability of the findings to other pediatric demographic groups

C. Clinical Pharmacology:

1. The primary pharmacokinetics (PK) endpoints include assessment of:
 - a. PK parameters of total IgG evaluated in subset of subjects (PK population)
 - b. Trough serum total IgG levels before each infusion of GC5107 in all subjects.
2. A total of 27 subjects comprised the PK population of which 15 subjects treated with the 28-day infusion and 12 subjects treated with the 21-day infusion schedule.
3. PK was evaluated after the 5th infusion (~5x half-life) and hence the PK parameters reflect steady state condition. The summary of dosing administered during the PK evaluation is shown below:

Age Group	Dose (mg/kg)
21-Day Dosing Regimen	
(b) (4)	
28-Day Dosing Regimen	
(b) (4)	
>= 17 years (n=13)	507±104 (313-691)

4. PK data from children are not available to fully evaluate the impact of age. Per FDA guidance for IGIV, the recommended sample size for PK studies for each pediatric age group is 6 to 12 subjects, you have PK data from (b) (4)

The half-life values in adult subjects were 20 ± 5.5 days (n=6). Please discuss the (b) (4)

D. DMPQ (CMC-Facility):

1. Please provide the manufacturing schedule for October-December 2021 at your Ochang facility for the IGIV 10% drug substance and drug product manufacturing.
2. We are currently in the process of determining the feasibility and working on the logistics regarding performing an RIE. Communication between CBER/DMPQ and GCC representatives regarding an RIE is ongoing.

2. Information regarding major safety concerns.

At this time, no major safety concerns have been identified.

3. Preliminary Review Committee thinking regarding risk management.

At this time, there is no discussion for risk management.

4. Information requests sent, and responses not received:

- a. Manufacturing facility IR sent on August 6, 2021; requested GCC response due August 13, 2021.

5. Any new information requests to be communicated.

The review team has no new information requests to be communicated at this time.

6. Proposed dates for the Late-Cycle Meeting (LCM) and the Late-Cycle Meeting Materials:

- a. The LCM between you and the review committee is currently scheduled for November 5, 2021, and the LCM Materials will be sent on or before October 26, 2021.
- b. If these timelines change, we will communicate updates to you during the course of the review.

7. Updates regarding plans for the Advisory Committee meeting, if appropriate.

There are no plans to present this Biologics License Application to the Advisory Committee at this time.

8. Other projected milestone dates for the remainder of the review cycle, including changes to previously communicated dates.

Tentative Labeling Target Date: January 26, 2022

Tentative Postmarketing Commitment (PMC) Target Date: January 26, 2022